

# **Global Ovarian Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023**

<https://marketpublishers.com/r/GD14D287B29EN.html>

Date: October 2017

Pages: 209

Price: US\$ 4,400.00 (Single User License)

ID: GD14D287B29EN

## **Abstracts**

Global Ovarian Cancer Treatment Market:

Global ovarian cancer treatment market estimated to be valued US\$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for ovarian cancer treatment is projected to reach US\$ XX Mn by 2023.

Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer.

Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals

regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplalin are expected to hamper the ovarian cancer treatment market.

Ovarian cancer treatment market segmented on the basis of type of cancer, drug class, and stage

Based on type of cancer, ovarian cancer treatment market is segmented into

- Epithelial Ovarian Tumor
- Ovarian Germ Cell Tumor
- Ovarian Stomatal Tumor
- Primary Peritoneal Carcinoma

Based on drug class, ovarian cancer treatment market is segmented into

- Chemotherapeutic Agents
- Targeted Therapy Drugs
- Immune System Modulators
- Hormones

Based on distribution channel, ovarian cancer treatment market is segmented into

- Hospital Pharmacies
- Retail Pharmacies
- Others

Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.

Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.

Some of the players in ovarian cancer treatment market include Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia), Aeterna Zentaris Inc. (U.S.), GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) to name a few.

In December 2016 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation

## **REPORT OUTLINE:**

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL OVARIAN CANCER TREATMENT MARKET INTRODUCTION**

2.1. Global Ovarian Cancer Treatment Market– Taxonomy

2.2. Global Ovarian Cancer Treatment Market–Definitions

2.2.1. Drug Class

2.2.2. Cancer Type

### **3. GLOBAL OVARIAN CANCER TREATMENT MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Ovarian Cancer Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Ovarian Cancer Treatment Market– Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.7. Global Ovarian Cancer Treatment Market– Recent Product Launches

### **4. GLOBAL OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL OVARIAN CANCER TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023**

5.1. Chemotherapeutic Agents

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Targeted Therapy Drugs

- 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis
- 5.3. Immune System Modulators
  - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.3.3. Market Opportunity Analysis
- 5.4. Hormones
  - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 5.4.3. Market Opportunity Analysis

## **6. GLOBAL OVARIAN CANCER TREATMENT MARKET FORECAST, BY CANCER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 6.1. Epithelial Ovarian Tumor
  - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.1.3. Market Opportunity Analysis
- 6.2. Ovarian Germ Cell Tumor
  - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.2.3. Market Opportunity Analysis
- 6.3. Ovarian Stomatal Tumor
  - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 6.3.3. Market Opportunity Analysis

## **7. GLOBAL OVARIAN CANCER TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023**

- 7.1. Hospital Pharmacies
  - 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 7.1.3. Market Opportunity Analysis
- 7.2. Retail Pharmacies
  - 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  - 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  - 7.2.3. Market Opportunity Analysis

### 7.3. Others

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

## **8. GLOBAL OVARIAN CANCER TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

### 8.2. Europe

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.2.3. Market Opportunity Analysis

### 8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.3.3. Market Opportunity Analysis

### 8.4. Latin America

- 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.4.3. Market Opportunity Analysis

### 8.5. Middle East and Africa

- 8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.5.3. Market Opportunity Analysis

### 8.6. Global Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2017 – 2023

## **9. NORTH AMERICA OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 9.1.1.1. Chemotherapeutic Agents
- 9.1.1.2. Targeted Therapy Drugs
- 9.1.1.3. Immune System Modulators

9.1.1.4. Hormones

9.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Epithelial Ovarian Tumor

9.1.2.2. Ovarian Germ Cell Tumor

9.1.2.3. Ovarian Stomatal Tumor

9.1.2.4. Primary Peritoneal Carcinoma

9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospital Pharmacies

9.1.3.2. Retail Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

9.1.6. North America Ovarian Cancer Treatment Market Dynamics – Trends

## **10. EUROPE OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Chemotherapeutic Agents

10.1.1.2. Targeted Therapy Drugs

10.1.1.3. Immune System Modulators

10.1.1.4. Hormones

10.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Epithelial Ovarian Tumor

10.1.2.2. Ovarian Germ Cell Tumor

10.1.2.3. Ovarian Stomatal Tumor

10.1.2.4. Primary Peritoneal Carcinoma

10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospital Pharmacies

10.1.3.2. Retail Pharmacies



10.1.3.3. Others

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

10.1.6. Europe Ovarian Cancer Treatment Market Dynamics – Trends

## **11. ASIA-PACIFIC OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Chemotherapeutic Agents

11.1.1.2. Targeted Therapy Drugs

11.1.1.3. Immune System Modulators

11.1.1.4. Hormones

11.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Epithelial Ovarian Tumor

11.1.2.2. Ovarian Germ Cell Tumor

11.1.2.3. Ovarian Stomatal Tumor

11.1.2.4. Primary Peritoneal Carcinoma

11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospital Pharmacies

11.1.3.2. Retail Pharmacies

11.1.3.3. Others

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Ovarian Cancer Treatment Market- Opportunity Analysis Index -  
By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

11.1.6. Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends

## **12. LATIN AMERICA OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue  
(USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Chemotherapeutic Agents

12.1.1.2. Targeted Therapy Drugs

12.1.1.3. Immune System Modulators

12.1.1.4. Hormones

12.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue  
(USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Epithelial Ovarian Tumor

12.1.2.2. Ovarian Germ Cell Tumor

12.1.2.3. Ovarian Stromal Tumor

12.1.2.4. Primary Peritoneal Carcinoma

12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by  
Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospital Pharmacies

12.1.3.2. Retail Pharmacies

12.1.3.3. Others

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD  
Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Ovarian Cancer Treatment Market- Opportunity Analysis Index -  
By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

12.1.6. Latin America Ovarian Cancer Treatment Market Dynamics – Trends

## **13. MIDDLE EAST & AFRICA OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 13.1.1.1. Chemotherapeutic Agents
- 13.1.1.2. Targeted Therapy Drugs
- 13.1.1.3. Immune System Modulators
- 13.1.1.4. Hormones

13.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 13.1.2.1. Epithelial Ovarian Tumor
- 13.1.2.2. Ovarian Germ Cell Tumor
- 13.1.2.3. Ovarian Stomatal Tumor
- 13.1.2.4. Primary Peritoneal Carcinoma

13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 13.1.3.1. Hospital Pharmacies
- 13.1.3.2. Retail Pharmacies
- 13.1.3.3. Others

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 13.1.4.1. Gulf Cooperation Council (GCC) Countries
- 13.1.4.2. Israel
- 13.1.4.3. South Africa
- 13.1.4.4. Rest of MEA

13.1.5. MEA Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023

13.1.6. MEA Ovarian Cancer Treatment Market Dynamics – Trends

## **14. COMPETITION LANDSCAPE**

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

- 14.2.1. Eli Lilly and Company (U.S.)
- 14.2.2. Johnson & Johnson Services, Inc. (U.S.)
- 14.2.3. Novogen Limited (Australia)

14.2.4. Aeterna Zentaris Inc. (U.S)

14.2.5. GlaxoSmithKline plc (UK)

14.2.6. Boehringer Ingelheim GmbH (Germany)

14.2.7. F. Hoffmann-La Roche AG (Switzerland)

## **15. RESEARCH METHODOLOGY**

## **16. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Global Ovarian Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/GD14D287B29EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD14D287B29EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

